| Also known as |
7-[(3R)-3-Amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine phosphate (1:1) |
| Blood pressure |
Generally has a neutral effect on blood pressure |
| Chemical name |
Sitagliptin phosphate |
| Dosage (medical) |
Typically 100 mg once daily |
| Dosage (sports) |
Not applicable |
| Effects |
Improves blood glucose control |
| Formula |
C16H15F6N5O•H3PO4 |
| Half-life |
Approximately 12.4 hours |
| Hepatotoxicity |
Low risk |
| Lab Test |
Monitoring of blood glucose and HbA1c levels |
| Main action |
Increases insulin release and decreases glucagon levels in a glucose-dependent manner |
| Raw Material |
Sitaggliptin |
| Side effects |
Nasopharyngitis, headache, upper respiratory tract infection, hypoglycemia (when used with other antidiabetics) |
| Storage conditions |
Store at room temperature, away from moisture and heat |
| Substance class |
Dipeptidyl peptidase-4 (DPP-4) inhibitor |
| Trade name |
Januvia |
| Use in sports |
Not typically used in sports |
| Water Retention |
No significant effect |
| Manufacturer |
MERCK |
| Packing |
28 tabs (100 mg/tab) |
